Glucosamine

No national clinical organizations recommend use of glucosamine for relief from arthritis. These include medical associations in Australia, Canada, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, the United Kingdom National Institute for Health and Care Excellence, the United States National Center for Complementary and Integrative Health, Recommendations against use Several clinical organizations have explicitly recommended against use of glucosamine to treat arthritis, stating that it has not been proven to be effective, that it may have negative interactions with prescription drugs, and that it may cause allergic reactions in people sensitive to shellfish, a common starting material in glucosamine manufacturing. The American College of Rheumatology and American Arthritis Foundation stated that "glucosamine is strongly recommended against in patients with knee, hip, and/or hand osteoarthritis". ==Dietary supplement==

Oral glucosamine is a dietary supplement and is not a prescription drug in the United States. As is common with heavily promoted dietary supplements, the claimed benefits of glucosamine are based principally on individual clinical and laboratory studies. Clinical studies on glucosamine efficacy are divided, ==Adverse effects and drug interactions==

Glucosamine with or without chondroitin elevates the international normalized ratio (INR) in individuals who are taking the anticoagulant warfarin. Many manufacturers of glucosamine derived from shellfish include a warning that those with a seafood allergy should consult a healthcare professional before taking the product. Another concern has been that the extra glucosamine could contribute to incident diabetes by interfering with the normal regulation of the hexosamine biosynthesis pathway. ==Biochemistry==

Glucosamine is naturally present in the shells (exoskeletons) of shellfish, animal bones, bone marrow, and fungi. -Glucosamine is made naturally in the form of glucosamine-6-phosphate, and is the biochemical precursor of all nitrogen-containing sugars. Specifically in humans, glucosamine-6-phosphate is synthesized from fructose 6-phosphate and glutamine by glutamine—fructose-6-phosphate transaminase as the first step of the hexosamine biosynthesis pathway. The end-product of this pathway is uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which is then used for making glycosaminoglycans, proteoglycans, and glycolipids. As the formation of glucosamine-6-phosphate is the first step for the synthesis of these products, glucosamine may be important in regulating their production; however, the way that the hexosamine biosynthesis pathway is actually regulated, and whether this could be involved in contributing to human disease remains unclear. ==Manufacturing==

Most glucosamine is manufactured by processing chitin from the exoskeletons of shellfish, including shrimp, lobsters, and crabs. To meet the demands of vegetarians and others with objections to shellfish, manufacturers have brought glucosamine products to market made using fungus Aspergillus niger and from fermenting corn. ==History==

Glucosamine was first prepared in 1876 by Georg Ledderhose by the hydrolysis of chitin with concentrated hydrochloric acid. The stereochemistry was not fully determined until the 1939 work of Walter Haworth. == Legal status ==

United States In the United States, glucosamine is not approved by the Food and Drug Administration (FDA) for medical use in humans. Because glucosamine is classified as a dietary supplement in the United States, the FDA requires evidence of its safety, but not its effectiveness, as long as it is not marketed as a treatment for any medical condition. In 2004, the FDA declared there was insufficient evidence for supplement manufacturers to state that glucosamine was effective for treating arthritis, joint degeneration, or cartilage deterioration, a position remaining in effect, as of 2025. Europe In most of Europe, glucosamine is approved as a medical drug and is sold in the form of glucosamine sulfate. By 2014, OARSI no longer recommended glucosamine for disease modification and deemed its effectiveness for symptom relief in knee osteoarthritis as "uncertain." A 2016 review concluded that only the formulated prescription-only patented crystalline glucosamine sulfate had efficacy in the treatment of arthritis. In August 2012, a class-action lawsuit was filed in New York claiming that 21st Century Healthcare, Inc. had falsely advertised that its "Glucosamine 750 Chondroitin 600 Triple Strength" dietary supplements would restore lost cartilage. In April 2013, a San Diego man launched a proposed class-action lawsuit in the United States District Court for the Central District of California accusing Nutramax Laboratories, Walmart, and Rite Aid of falsely advertising the effectiveness of glucosamine. ==Research==

Humans Because glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of cartilage, research has focused on the potential for supplemental glucosamine to improve cartilage structure and alleviate arthritis, but there is little evidence from clinical trials that it is effective for alleviating arthritis pain. Bioavailability Two studies measured the concentrations of glucosamine in the synovial fluid and plasma after oral administration of glucosamine sulfate to both healthy volunteers and people with osteoarthritis. In the first study, glucosamine sulfate was given to healthy volunteers in doses of 750, 1,500, or 3,000 mg once daily. In the second study, oral glucosamine sulfate capsules (1,500 mg) were given daily for two weeks to 12 people with osteoarthritis. Glucosamine concentrations in plasma and synovial fluid increased significantly from baseline levels, and the levels in the two fluids were highly correlated. The authors interpreted that these levels could be biologically advantageous to articular cartilage, but the levels are still ten to one hundred times lower than required to positively influence the cartilage (chondrocytes) to build new tissue. Glucosamine sulfate uptake in synovial fluid may be as much as 20%, or it could be negligible, indicating no biological significance. ==Veterinary medicine==

Dogs Some studies have demonstrated efficacy of glucosamine supplementation for dogs with osteoarthritis pain, particularly in combination with other nutraceuticals like chondroitin, while others have not. A trial of oral combination capsules (glucosamine, chondroitin, and manganese ascorbate) in dogs with osteoarthritis found no benefit on either gait analysis or subjective assessments by the veterinarian or owner. Several studies have measured the bioavailability of glucosamine after oral administration to horses. When given as a single oral dose (9 g) with or without chondroitin sulfate (3 g) to ten horses, glucosamine (hydrochloride) was detected in the blood with a maximum level of at two hours after dosing. Another study examined both the serum and the joint synovial fluid after nasogastric (oral) or intravenous administration of 20 mg/kg glucosamine hydrochloride to eight adult horses. Although joint fluid concentrations of glucosamine reached 9–15 μmol/L following intravenous dosing, it was only 0.3–0.7 μmol/L with nasogastric dosing. The authors calculated that these glucosamine synovial fluid levels achieved by the oral route were 500 times lower than required to positively affect the metabolism of cartilage cells. A follow-up study by the same research group compared glucosamine sulfate with glucosamine hydrochloride at the same dose (20 mg/kg) in eight horses and found a higher fluid concentration with the sulfate preparation (158 ng/mL compared to 89 ng/mL one hour post oral dose). They concluded that these higher synovial fluid levels obtained with the sulfate derivative were still too low to have a relevant biological effect on articular cartilage. A three-month trial of an oral dosage regime of a commercial preparation of glucosamine sulfate, chondroitin sulfate, and methylsulfonylmethane was performed in veteran horses with no effect on gait stiffness, with exercise alone in the control group being effective. The intravenous use of a combination of N-acetylglucosamine, pentosan polysulfate, and sodium hyaluronate in horses with surgically-induced osteoarthritis saw improvements in X-ray changes to the cartilage but not histologically or in biochemical outcomes, suggesting more evidence is needed for this combination and route of administration. ==See also==